Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Hospira
Hospira
Activities:
Drug Delivery
Pharmaceutical
A global specialty pharmaceutical and medication delivery company.
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Regulatory
FDA cautions Pfizer subsidiary in India in quality control warning letter
The letter is the result of an inspection at Hospira Healthcare India that identified GMP violations in quality control, data integrity, and microbial control
Drug Delivery
Mylan and Hospira voluntarily recall injectables
Glass and copper salts were found in the companies’ injectable medications but no adverse reactions have been reported as yet
Regulatory
Brussels explains why it approved Pfizer/Hospira deal
Pfizer made a commitment to remove possible product overlaps between the two companies
Regulatory
Hospira calls for biosimilars to have same name as biologicals
Different names for a biologic and the biosimilar medicine patterned on that biologic could create confusion among clinicians
Research & Development
Hospira and Pfenex link up to develop Lucentis biosimilar
Pfenex will receive US$51m upfront once the collaboration receives antitrust approval
Drug Delivery
Pfizer to acquire Hospira
Pfizer and Hospira have entered into a definitive merger agreement under which Pfizer will acquire Hospira
Manufacturing
Opinion: Still not getting it right
The future for pharma development is bright, but there are still too many potentially dangerous recalls in the manufacturing sector
Subscribe now